- Home
- GTN vs AUTL Comparison
GTN vs AUTL Comparison
Compare GTN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTN | AUTL |
|---|---|---|
| Founded | 1897 | 2014 |
| Country | United States | United Kingdom |
| Employees | 9582 | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.5M | 388.6M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GTN | AUTL |
|---|---|---|
| Price | $4.11 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $13.89 | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $3.50 | $1.18 |
| 52 Week High | $6.44 | $2.70 |
Technical Indicators
Market Signals| Indicator | GTN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 49.39 |
| Support Level | $3.83 | $1.38 |
| Resistance Level | $4.21 | $1.73 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 72.17 | 46.15 |
Price Performance
Historical ComparisonAbout GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.